RNAi Roundtable: Patisiran and Revusiran for the treatment of Transthyretin (TTR)-Mediated Amyloidosis

RNAi Roundtable: Patisiran and Revusiran for the treatment of Transthyretin (TTR)-Mediated Amyloidosis

On August 20, 2015, we hosted an online RNAi Roundtable to review the progress with patisiran and revusiran in development for the treatment of transthyretin (TTR)-mediated amyloidosis.

View the presentation
Read the transcript



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.